Decreased â-phenylethylamine in CSF in Parkinson’s disease

Objective—To determine the concentrations of â-phenylethylamine (PEA) in CSF in patients with Parkinson’s disease, and to evaluate the relation between concentration of PEA in CSF and severity of Parkinson’s disease. Methods—Using gas chromatographychemical ionisation mass spectrometry, CSF concentrations of PEA were measured in 23 patients with Parkinson’s disease (mean age, 64.0 (SD 8.2) years), of whom three were at Hoehn and Yahr stage II, 11 were at stage III, and nine were at stage IV. Comparison was made with eight patients with neuropathy (mean age, 57.0 (SD 19.2) years) and 12 controls without neurological disease (mean age, 57.6 (SD 4.8) years). Results—Concentrations of PEA in CSF in Parkinson’s disease were significantly lower (mean 205 (SD 131) pg/ml) than in patients with peripheral neuropathy (433 (SD 254) pg/ml) and controls (387 (SD 194) pg/ml). The concentrations of PEA in CSF correlated negatively with Hoehn and Yahr stage (P<0.01). Conclusions—There are decreased CSF concentrations of PEA in patients with Parkinson’s disease. (J Neurol Neurosurg Psychiatry 1997;63:754–758)